BioSpace News Archive

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations will participate in an Analyst-Moderated fireside chat at the Wells Fargo 2020 Virtual Healthcare Conference on Thursday, September 10, 2020 at 3:20 p.m. Eastern Time. This presentation will be

Upsized IPO in July 2020 raised $128.8 million in gross proceeds Submitted IND for INZ-701 for the treatment of ENPP1 deficiency; currently on FDA clinical hold pending completion of ongoing GLP toxicology studies Initiation of INZ-701 Phase 1/2 clinical trials anticipated in early 2021, as previously planned BOSTON, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of di

Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today announced that four abstracts have been accepted for presentation, including a late-breaker, at the upcoming 8 th Joint Congress of the American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Res

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that that members of its senior management team will participate in the upcoming investor conferences: Wells Fargo Virtual Healthcare Conference – Presenting on Wednesday, September 9 , at 1:20 PM ET Citi 2020 BioPharma Virtual Conference – Hosting investor meetings

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will present at the H.C. Wainwright 22 nd Annual Global Investment Conference on Tuesday, September 15 at 3 p.m. ET. Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present virtually to provide an update on the development of Ocugen’s breakthrough

MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company’s management will participate in the following investor conferences in September:

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today provides an update on progress for the U.S. manufacturing of Berubicin, the Company’s lead drug candidate, in preparation for upcoming clinical trials. As previously announced, the Company implemented a dual

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the Company is scheduled to present at two upcoming healthcare investor conferences: Baird 2020 Global Healthcare Conference Date: Thursday, September 10, 2020 Presentation Time: 11:25 a.m. ET Morgan Stanley 18th Annual Global He

Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced the appointment of Robert Ross , M.D., to its Board of Directors. Dr. Ross currently s

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming virtual investor conferences: Baird 2020 Virtual Global Healthcare Confere